CCS/ESC JOINT PLENARY: MULTIMODALITY IMAGING FOR THE DX AND MANAGEMENT OF HEART FAILURE (CCC-123)

Thursday, October 26, 2023

14:00 – 15:00 EST

Location: Palais, 517D

Target Audience: General: All cardiovascular (clinical and research) health professionals, Echocardiologists, Heart failure specialists, Trainee

Co-Chair(s)

Anna Baritussio

Consultant Cardiologist
University Hospital Padua
University of Padua Department of Cardiac Thoracic and Vascular Scienc
SM

Sharon L. Mulvagh, MD

Professor of Medicine
CSE
Dalhousie University

Presenter(s)

Anita Chan

Cardiologist
Mazankowski Alberta Heart Institute
University of Alberta
Tahir Kafil, MD, FRCPC

Advanced Clinical Fellow
Cleveland Clinic Foundation
Cleveland Clinic Foundation
Andreas Kumar, MD MSc

Associate Professor of Medicine
Northern Ontario School of Medicine
Northern Ontario School of Medicine

Planning Committee Member(s)

Margot K. Davis, MD, MS, FRCPC, FCCS (she/her/hers)

Clinical Associate Professor
CHFS, CCTN, CCON
University of British Columbia
Tara D'Ignazio

PGY-6 Cardiology
Université de Montréal
Université de Montréal
Robin A. Ducas, MD

Assistant Professor
University of Manitoba
University of Manitoba
Robert JH Miller, MD (he/him/his)

Clinical Associate Professor
Libin Cardiovascular Institute of Alberta
University of Calgary, Libin Cardiovascular Institute
Dinesh Thavendiranathan, MD, FRCPC

Director, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, TGH
Toronto General Hospital
University of Toronto

Disclosure(s):

Anna Baritussio: No financial relationships to disclose

Sharon L. Mulvagh, MD: Lantheus Medical Imaging: Consultant/Advisory Board (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing)

Anita Chan: Pfizer Canada: Consultant/Advisory Board (Terminated), Speaker/Honoraria (Terminated)

Tahir Kafil, MD, FRCPC: No financial relationships to disclose

Margot K. Davis, MD, MS, FRCPC, FCCS: Alnylam: Speaker/Honoraria (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); BI/Lilly: Consultant/Advisory Board (Ongoing); Eidos: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Ferring: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Tara D'Ignazio: No financial relationships to disclose

Robin A. Ducas, MD: No financial relationships to disclose

Robert JH Miller, MD: Pfizer: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

describe the initial role of Echocardiography in determining the phenotype of clinical CHF;
identify the clinical situations in which cardiac MRI offers incremental value in the workup of CHF;
discuss the role of nuclear imaging in the evaluation of CHF patients; and
develop a framework for selecting the optimal imaging test in the workup of CHF.

Session Description: Dr. Tahir Kafil, a CCS HF Trainee will present a generic case with standard echo imaging only, inviting speakers to offer ways that their imaging modality could help determine etiology, including:

Andrew Kumar, CCS: CMR

Anita Chan, CCS: Nuclear

Anna Baritussio, ESC: ECHO